# Master Assumptions Review — March 2026

Full peer review of 123 stock records across 5 parallel agents. Generated 2026-03-18.

---

## Priority 1: Data Integrity Bugs

These produce wrong CAGR outputs or contain verifiable factual errors. Fix first.

| Ticker | Bug | Correct Value |
|--------|-----|---------------|
| **NFLX** | `ttmEPS: 2.53` — FY2025 non-GAAP EPS is ~$19-22; invalidates all CAGR scenarios | ~20.0 |
| **NOW** | Split factor: basis says "5-for-1" but ServiceNow did 10-for-1 (Feb 2025); `ttmEPS: 2.70` at `$116.72` implies 43x PE but file shows 23.2x forward | Verify & reconcile |
| **SMSN.IL** | `dividendYield: 43%` — KRW/GBX unit mismatch vs USD price; Samsung yield ~2-3%; corrupts screener routing | ~2-3% |
| **HALO** | `bullCase` claims "~12% FCF yield" but `metrics.fcfYield` shows ~2% — direct contradiction | Fix bullCase text |
| **DHR** | `bullCase` + `bearCase` both reference "Masimo acquisition" — Danaher acquired **Abcam** ($5.7B, 2023); Masimo is a separate company | Replace "Masimo" → "Abcam" |
| **NVO** | `bullCase` calls CagriSema "best-in-class efficacy potential" — Phase 3 showed 22.7% weight loss vs 25%+ expected; factually incorrect | Update bullCase |
| **GOOGL** | `confidenceReason` says "12.3% discount to DCF" — `intrinsicValue.dcf: $159.47` at price $310 means stock is ~95% **above** DCF | Fix confidenceReason |
| **AVGO** | `sharpeRatio: 0.15` but `confidenceReason` says "Sharpe 0.50" | Reconcile |
| **CSU.TO** | `sharpeRatio: 0.13` but `confidenceReason` says "Elite Sharpe (0.85)" | Fix confidenceReason |
| **TOI.V** | `sharpeRatio: 0.46` but `confidenceReason` says "Strong Sharpe (0.75)" | Fix confidenceReason |
| **TVK.TO** | `sharpeRatio: 0` — suspicious data error | Investigate feed |
| **ISRG** | `basis` note says "bear assumes compression to 35x" but `exitPE.bear: 45` — direct contradiction | Lower bear to 35 or fix note |
| **SNPS** | `bearCase` text says "~2.5x Net Debt/EBITDA" but `metrics.netDebtEbitda: 5.4x` post-Ansys | Fix bearCase to 5.4x |
| **VIT-B.ST** | `screener.score: 0.74` (PASS threshold ≤1.0) but `signal: FAIL` — contradicts system rules; no `note` explaining override | Fix signal or add note |
| **MKTX** | `confidenceReason` says gaining market share — MKTX is losing share to TW; revenue flat 2023-2024 | Rewrite confidenceReason |

---

## Priority 2: Wrong Screener Engine

| Ticker | Current | Problem | Correct |
|--------|---------|---------|---------|
| **MKL** | totalReturn | `dividendYield: 0%` — totalReturn requires ≥5%; MKL pays no dividend | fPERG |
| **LNG** | totalReturn | `dividendYield: 1%` — far below 5% threshold | fEVG or fPERG |
| **TFPM** | totalReturn | `dividendYield: 1%` — far below 5% threshold | fCFG |
| **KYCCF** | totalReturn | `dividendYield: 1%` — far below 5% threshold | fPERG |

---

## Priority 3: exitPE Too Low (Systematic Undervaluation)

| Ticker | Current (bear/base/bull) | Should Be | Reason |
|--------|--------------------------|-----------|--------|
| **SPGI** | 15/20/25 | **28/35/42** | Financial data/SaaS — historically 30-45x non-GAAP |
| **MCO** | 15/20/25 | **28/35/42** | Duopoly peer of SPGI |
| **TW** | 15/20/25 | **30/40/50** | Electronic marketplace — historically 40-55x; bear CAGR currently -1% (wrong) |
| **IT** | 15/20/25 | **28/35/42** | Financial data/SaaS monopoly |
| **OWL** | 8/10/13 | **18/22/27** | Alt asset manager benchmark; 8x is distress pricing |
| **KNSL** | 15/20/25 | **20/25/32** | Specialty insurance benchmark |
| **CRDO** | 20/25/35 | **30/40/55** | 35% grower → hyper-growth tier; base 25x below current fwd PE |
| **ARGX** | 25/30/35 | **30/38/50** | High-growth biotech domain rule (>20% EPS growth) |
| **HWM** | 15/20/25 | **22/28/34** | Aerospace domain rule; model gives -14% to -5% CAGR for a 15% grower |
| **RGLD** | 18/24/30 | **20/26/32** | Royalty streamer floor is 20/26/32 |
| **TFPM** | 18/23/28 | **20/26/32** | All three below royalty streamer floor |
| **ET** | 8/11/14 | **10/12/15** | MLP domain: bear ≥10, base ≥12 |
| **INDT.ST** | 15/20/25 | **18/24/30** | Swedish industrial floor 18/22/28 |
| **LAGR-B.ST** | 15/20/25 | **18/24/30** | Swedish industrial floor; bear 15 below rule |
| **ZTS** | 30/35/40 | **20/26/32** | Trades at 16x forward; bear 30 assumes huge re-rating even in downside |
| **ICLR** | 15/20/25 | **18/22/28** | CRO domain rule |
| **MEDP** | 15/20/25 | **20/27/33** | CRO domain rule |
| **URI** | 10/14/18 | **16/20/24** | Industrial compounder; bear 10 is depression-era pricing |
| **WSO** | 15/20/25 | **18/22/26** | HVAC domain: bear ≥18 |
| **JDG.L** | 15/20/25 | **18/24/30** | UK compounder: bear ≥18 |
| **NU** | 20/25/30 | **22/30/42** | EM fintech; bull 30 should be ~40-45 |
| **PSK.TO** | 15/20/25 | **18/24/28** | Royalty; stock at 37x forward, bull 25 always implies compression |
| **BABA** | 15/20/25 | **10/14/18** | Chinese internet discount; bear 15 above VIE-crisis historical lows |
| **0700.HK** | 16/20/25 | **12/16/22** | Chinese internet discount |
| **MKTX** | 15/20/25 | **22/30/40** | Electronic marketplace — historically 35-50x |

---

## Priority 4: exitPE Too High

| Ticker | Current | Should Be | Reason |
|--------|---------|-----------|--------|
| **NVO** | 25/30/35 | **14/20/25** | Trailing only 10.9x; DKK/USD ADR distortion |
| **CDNS** | 42/52/62 | **35/42/52** | Above EDA domain ceiling |
| **TOI.V** | 43/54/65 | **30/38/50** | Significantly above Canadian compounder guidelines |
| **CSU.TO** | 35/45/55 | **28/38/48** | Slightly above guidelines; basis note references "exit PE 68" not in model |
| **TDG** | 37/46/55 | **28/36/44** | Aerospace domain ceiling 42; needs explicit override justification |
| **SE** | 20/25/30 | **22/32/45** | Actually too LOW for EM fintech — base/bull dramatically understate upside |

---

## Priority 5: Missing bullCase / bearCase (~30 stocks)

| Sector | Tickers |
|--------|---------|
| US Tech | AMD, LRCX, AMAT, ALAB, CRDO, AAPL, AMZN, MSFT, NFLX |
| Healthcare/Growth | ZTS, BKNG, MCK, COR, IT, FTNT, UBER, ICLR |
| Financials | ARES, IBKR, SPGI, MCO, TW, MKTX, KNSL, VRSK |
| International | DSG.TO, JDG.L |
| Energy/Industrials | HWM, WST, WSO, URI, CPRT, TPZ.TO, PSK.TO, INDT.ST, LAGR-B.ST |

---

## Priority 6: Missing cyclical:true (~25 stocks)

| Sector | Tickers |
|--------|---------|
| Semiconductors/Semicap | NVDA, AMD, AVGO, ANET, MRVL, TSM, ASML, LRCX, AMAT |
| Financials/Alts | KKR, APO, BRK.B, IBKR, BN, EQT.ST, INVE-B.ST |
| International/EM | SE, BABA, 0700.HK, NU, TVK.TO, EXO.AS, KAP.IL |
| Energy/Royalties | LNG, ET, TPL, VNOM, FNV, RGLD, WPM, TFPM |
| Industrials/Aerospace | TDG, HWM, HEI, HEI.A, URI, DHR, MTRN, VRT |
| Consumer/Ad-Tech | APP, BKNG, UBER, META |

---

## Priority 7: Group Misclassifications

| Ticker | From | To | Reason |
|--------|------|----|--------|
| ANET | AI & Semiconductors | Network Infrastructure | Makes Ethernet switches, not chips |
| DDOG | Cybersecurity | Cloud Infrastructure | Observability/monitoring, not security |
| GOOGL | Defensive Monopolies | Data & Software Monopolies | Ad revenue is procyclical |
| META | Defensive Monopolies | Data & Software Monopolies | 97% ad-dependent; procyclical |
| CRM | Defensive Monopolies | Data & Software Monopolies | Inconsistent with MSFT placement |
| UBER | Data & Software Monopolies | Marketplace Platforms | Two-sided marketplace with direct competitors |
| FTNT | Data & Software Monopolies | Cybersecurity | Consistent with CRWD/PANW/ZS |
| NVO | Healthcare Monopolies | Large-Cap Pharma | GLP-1 moat now actively contested by LLY |
| ICLR | Healthcare Monopolies | Healthcare Services | CRO competes with IQVIA, Syneos |
| MEDP | Healthcare Monopolies | Healthcare Services | Same rationale as ICLR |
| EXEL | Healthcare Monopolies | Biotech | Single-asset oncology; no monopoly position |
| HALO | Biotech | Healthcare Technology | Drug delivery licensor/royalty platform |
| SHOP | Defensive Monopolies | High-Growth Tech | GMV tied to consumer spending cycles |
| TW | Financials & Alt Assets | Data & Software Monopolies | Electronic marketplace, not PE/VC |
| MKTX | Financials & Alt Assets | Data & Software Monopolies | Same class as TW |
| IBKR | Financials & Alt Assets | Financial Services | Broker; fundamentally different from KKR/APO |
| KNSL | Financials & Alt Assets | Insurance Compounders | E&S specialty insurer |
| VRT | AI & Semiconductors | Industrial Monopolies | Power/cooling manufacturer |
| XYZ | Financials & Alt Assets | Fintech | Payments (Cash App + Square) |
| INVE-B.ST | The Capital Compounders | Capital Compounders | Remove non-standard leading "The" |

---

## Priority 8: epsGrowth Refinements

| Ticker | Current | Suggested | Reason |
|--------|---------|-----------|--------|
| AVGO | 28% | 23-25% | VMware synergies plateau; consensus 22-25% |
| MKTX | 15% | 9% | Losing share to TW; flat revenue 2023-2024 |
| NVO | 20% | 12-14% | CagriSema Phase 3 miss; LLY competition |
| SE | 30% | 20-25% | Garena structurally declining; -5.5% earnings miss |
| NBIX | 18% | 13-15% | -18.1% earnings miss; 11 down-revisions in 30d |
| UBER | 15% | 20-22% | Consensus 20-30%; own confidenceReason says "20-40%" |
| META | 14% | 18-20% | Operating leverage on 22-26% revenue growth |
| AMD | 30% | 25% | Consensus clusters 25-28% |
| URI | 15% | 8-10% | 15 down-revisions; infra spend decelerating |
| WSO | 15% | 9-11% | HVAC distributor organic growth is mid-single digit |
| MTRN | 15% | 10-12% | Specialty industrial consensus 8-12% |
| PSK.TO | 15% | 10-12% | Royalty organic growth; consensus 8-12% |
| ICLR | 15% | 8-12% | NIH cuts, biotech funding squeeze; stock -44% |
| MEDP | 15% | 10-14% | CRO headwinds; internal inconsistency with confidenceReason |
| FFH.TO | 10% | 13% | Historical 18%+ book value CAGR |

---

## Priority 9: Basis Field Cleanup

| Ticker | Issue | Fix |
|--------|-------|-----|
| MA, V | "5yr avg PE" (multiple, not earnings type) | "Non-GAAP EPS" |
| FICO | Describes growth thesis, not EPS type | "Non-GAAP EPS" |
| ANET, MRVL, CRM | Describe multiple rationale instead of earnings type | "GAAP/Non-GAAP EPS; [multiple note]" |
| EPD, ET | "GAAP EPS" for MLPs | "Distributable Cash Flow per unit" |
| ASML | No currency noted | Add "USD-equivalent ADR; EUR-denominated source" |
| AMZN | Vague "sum-of-parts" | "Non-GAAP Operating EPS" |
| META | Claims "Ex-Reality Labs" (not a reported metric) | "Non-GAAP EPS (GAAP adj. for SBC; Reality Labs included)" |

---

## Systemic Patterns

1. **15/20/25 PE default** applied incorrectly to 10+ high-quality businesses — most impactful single error class
2. **~30 stocks missing bullCase/bearCase** — most widespread data completeness gap
3. **~25 stocks missing cyclical:true** — affects deployment warnings system-wide
4. **4 stocks on wrong screener engine** (MKL, LNG, TFPM, KYCCF) — produces misleading signals
5. **Sharpe ratio desync** in 4 stocks (AVGO, CSU.TO, TOI.V, TVK.TO) — pipeline updated field but not confidenceReason text
6. **MLPs using GAAP EPS** (EPD, ET) — DCF/unit is industry standard; GAAP understates economics
7. **Chinese internet bear exit too generous** (BABA 15x, 0700.HK 16x) — above VIE-crisis historical trough multiples

---

*Previous batch analysis preserved below:*

# Stock Assumptions Analysis (Batch 1)

After reviewing the `cagrModel` assumptions for the provided stocks, here are the findings regarding their realism, particularly noting deviations or overly optimistic/pessimistic inputs:

### Significant Deviations & Unrealistic Assumptions

*   **ABBV (AbbVie):**
    *   **EPS Growth (15%):** Highly optimistic. Large-cap pharma companies rarely sustain 15% EPS growth over 5 years, especially with AbbVie facing the Humira patent cliff. A 5-10% range is much more realistic.
    *   **Exit P/E (Base 22):** Too optimistic. Mature pharmaceutical companies typically trade in the 15-18 P/E range.
*   **AMD (Advanced Micro Devices):**
    *   **EPS Growth (35%):** Extremely aggressive base case. While AI provides massive tailwinds, sustaining a 35% CAGR over 5 years extrapolates peak cycle growth into the long term. A base case of 15-25% would be more prudent.
*   **APP (AppLovin):**
    *   **EPS Growth (30%):** Highly optimistic. Ad-tech is notoriously cyclical and competitive. Sustaining 30% earnings growth for 5 years is a bull-case scenario, not a base case.
*   **ANET (Arista Networks):**
    *   **Exit P/E (Base 38):** Slightly optimistic. While growth is strong (20%), assigning a near-40x multiple to a networking hardware/software company 5 years from now assumes zero multiple compression as the company matures. A 25-30x exit P/E is more historically sound.

### Realistic / Reasonable Assumptions

*   **0700.HK (Tencent):** 15% EPS growth is achievable through aggressive buybacks and margin expansion, though slightly bullish given China's macro environment. 20x exit P/E is fair.
*   **ADDT-B.ST (Addtech):** 15% growth is in line with top-tier serial acquirers. 30x exit P/E is high but historically consistent for this specific Nordic compounder model.
*   **ADYEN.AS (Adyen):** 18% growth and a 35x exit P/E are realistic for a high-margin payments leader.
*   **APO (Apollo) & ARES (Ares):** 15-20% EPS growth and 16-20x exit P/Es are very reasonable and align well with structural tailwinds in alternative asset management.
*   **ARGX (argenx):** 27% growth and 30x P/E is plausible for a high-growth commercial-stage biotech, though inherently higher risk.


---

# Assumptions Analysis - Batch 2

**ASML Holding (ASML)**
*   **EPS Growth (18%):** Plausible given their EUV monopoly, but slightly optimistic considering geopolitical risks (China export bans) and industry cyclicality.
*   **Exit P/E (Base 36x):** Optimistic. While ASML commands a premium, assuming a 36x multiple five years out leaves little room for error if growth decelerates.

**Broadcom (AVGO)**
*   **EPS Growth (30%):** Highly optimistic. Sustaining 30% EPS CAGR over 5 years at a $1.5T market cap is extremely difficult, even with AI and VMware tailwinds.
*   **Exit P/E (Base 45x):** Very optimistic. Historically, AVGO traded in the 15-20x range. Assuming a 45x multiple as a base case implies permanent, extreme multiple expansion.

**Alibaba (BABA)**
*   **EPS Growth (13%):** Realistic, largely achievable through massive share repurchases and margin optimization, despite sluggish top-line growth.
*   **Exit P/E (Base 20x):** Slightly optimistic. Requires a significant rerating from current levels (Forward P/E ~15.8x) and a reduction in the "China geopolitical discount," which may persist.

**Booking Holdings (BKNG)**
*   **EPS Growth (15%):** Slightly optimistic for a mature OTA, though share buybacks heavily support this rate.
*   **Exit P/E (Base 20x):** Realistic for a high-margin, asset-light compounder with strong FCF.

**Brookfield Corporation (BN)**
*   **EPS Growth (25%):** Highly optimistic. While management targets this, sustaining 25% growth for a $1T+ AUM financial behemoth is very aggressive.
*   **Exit P/E (Base 18x):** Realistic for an alternative asset manager if growth targets are met.

**Berkshire Hathaway (BRK.B)**
*   **EPS Growth (6%):** Realistic and appropriately conservative for the massive capital base.
*   **Exit P/E (Base 22x):** Slightly optimistic. This is higher than its historical average multiple (often closer to 15-18x) and implies a premium valuation at exit.

**Cameco (CCJ)**
*   **EPS Growth (15%):** Unrealistic to model as linear growth. As a highly cyclical commodity producer, assuming steady 15% EPS growth ignores the boom/bust nature of uranium pricing.
*   **Exit P/E (Base 20x):** Flawed methodology. For cyclicals, peak earnings usually correspond with low P/E multiples, and trough earnings with high P/Es. Applying a structural 20x P/E is dangerous here.

**Cadence Design Systems (CDNS)**
*   **EPS Growth (20%):** Realistic given the structural EDA duopoly and sustained AI/chip design demand.
*   **Exit P/E (Base 52x):** Highly optimistic. Assuming the stock will still trade at 52x earnings after 5 years of compounding leaves absolutely zero margin of safety.

**Cencora (COR)**
*   **EPS Growth (15%):** Slightly optimistic. As a mature drug distributor, this relies heavily on massive share repurchases and price inflation, which may face regulatory pressure.
*   **Exit P/E (Base 20x):** Optimistic. Represents multiple expansion from current levels (Forward P/E 17.8x) for a very low-margin, structurally mature business.

**Copart (CPRT)**
*   **EPS Growth (15%):** Realistic based on historical consistency, but slightly optimistic as the law of large numbers sets in for their salvage monopoly.
*   **Exit P/E (Base 20x):** Realistic and aligns well with current multiples (Forward P/E 20.5x) and historical averages.

---

# Assumption Analysis - Batch 3

## CRM (Salesforce)
- **Growth (15%):** Realistic. A $50B buyback plan plus margin expansion supports 15% EPS growth even with slowing top-line revenue (8.4% YoY).
- **Valuation (Base P/E 28x):** Reasonable. A 28x terminal multiple is appropriate for an established SaaS monopoly.

## CRWD (CrowdStrike)
- **Growth (32%):** Aggressive but plausible. Sustaining 32% EPS growth over 5 years is difficult, but starts from a lower margin base with 30%+ revenue growth.
- **Valuation (Base P/E 40x):** Slightly optimistic. While growth is high, a 40x terminal multiple leaves little room for error, especially considering the reputational overhang from the 2024 outage.

## CSU.TO (Constellation Software)
- **Growth (18%):** Realistic. Historically consistent, though harder to maintain at a $54B market cap.
- **Valuation (Base P/E 68x):** Very optimistic. While CSU commands a historical premium, assuming a 68x terminal multiple in a normalized environment implies significant downside risk if compounding slows.

## DDOG (Datadog)
- **Growth (20%):** Realistic. Cloud observability is a structural tailwind.
- **Valuation (Base P/E 40x):** Fair. Standard for high-growth SaaS, but vulnerable to multiple compression if competition erodes margins.

## DHR (Danaher)
- **Growth (10%):** Realistic to Conservative. Coming off a trough in life sciences, 10% EPS growth for this historically elite compounder is highly achievable.
- **Valuation (Base P/E 32x):** Realistic. Consistent with their historical premium.

## DPLM.L (Diploma PLC)
- **Growth (16%):** Realistic. Supported by strong organic growth (14%) and M&A.
- **Valuation (Base P/E 36x):** Optimistic. A 36x terminal multiple is very rich for a technical products distributor, expecting elite premium valuations to persist indefinitely.

## DSG.TO (Descartes Systems)
- **Growth (15%):** Realistic.
- **Valuation (Base P/E 20x):** Conservative. A 20x exit P/E for a software monopoly with 32% FCF margins is a very grounded and safe assumption.

## EPD (Enterprise Products Partners)
- **Growth (6%):** Highly realistic. Matches historical slow-and-steady midstream compounding.
- **Valuation (Base P/E 13x):** Realistic. Appropriate for a top-tier MLP.

## EQT.ST (EQT AB)
- **Growth (20%):** Optimistic. Achieving 20% EPS/FRE growth over 5 years is tough given the noted "European macro stagnation" which could freeze IPO/M&A exits and carried interest.
- **Valuation (Base P/FRE 22x):** Reasonable for alternative asset managers.

## ET (Energy Transfer)
- **Growth (10%):** Optimistic. For a highly levered (4.6x net debt/EBITDA) midstream operator, sustaining double-digit EPS growth is challenging compared to the industry average.
- **Valuation (Base P/E 11x):** Realistic. Matches industry standards.

---

# Assumptions Analysis - Batch 4

Overall, the valuation models rely on sound fundamentals, but there are a few notable deviations where assumptions may be overly optimistic:

*   **EXEL (Exelixis):** The model assumes a base exit P/E of 20x (and bull of 25x), which is a significant multiple expansion from its current forward P/E of 10.5x. Given the noted "severe single-asset reliance" on Cabometyx and pipeline binary risks, the market is unlikely to award it a 20x multiple without major, de-risked pipeline success. This exit multiple assumption leans too optimistic.
*   **FNV (Franco-Nevada):** The 12% EPS growth assumption seems aggressive. The bull case relies heavily on revenue surging as "Cobre Panama potentially normalizes." Given that this is a complex geopolitical/regulatory issue, baking in normalization into the baseline growth rate carries high risk and may be too optimistic. 
*   **GOOGL (Alphabet):** Projecting a 15% EPS CAGR over the next 5 years for a $3.6T company is aggressive due to the law of large numbers. Furthermore, the file itself notes a "PEG ratio of 2.3x indicates slowing growth expectations," which contradicts the high 15% sustained growth assumption.

**Realistic/Conservative Models:**
*   **FTNT, HALO, FIH.U.TO:** These models correctly assume multiple compression or maintain very conservative exit multiples (e.g., HALO base exit P/E of 12x, FTNT base exit P/E of 20x) to account for patent cliffs, cyclicality, or emerging market risks, despite high projected growth rates. 
*   **FFH.TO, EXO.AS, HDB, FICO:** Assumptions for growth and multiples are historically grounded and realistic for their respective industries and moats.

---

# Assumptions Analysis: Batch 5

Based on financial principles and historical market norms, here is an analysis of the assumptions for the requested stocks:

## Overly Optimistic (High Multiple Risk)
*   **HEI (HEICO Corporation) & HEI.A:** Assume 16-18% EPS growth and extremely high base exit P/Es of 45x (HEI.A) and 52x (HEI). The bull case for HEI assumes a 62x exit P/E. Sustaining these multiples over a 5-year horizon leaves virtually no margin of safety and prices in absolute perfection. They are vulnerable to severe multiple compression.
*   **ISRG (Intuitive Surgical):** Models a 14% growth rate but with a base exit P/E of 55x (and 65x bull). While ISRG has a strong monopoly, projecting a >50x multiple 5 years out is highly optimistic as the company's growth naturally decelerates with scale.

## Highly Pessimistic (Severe Multiple Contraction)
*   **HWM (Howmet Aerospace):** Assumes a steep multiple contraction from its current ~43.6x forward P/E down to a 20x base exit P/E. While 20x is a normal industrial multiple, modeling a >50% multiple haircut results in a projected base CAGR of -14%. This may be overly pessimistic unless the aerospace cycle is definitively peaking.

## Realistic & Balanced (Steady Compounders)
*   **IBKR, INDT.ST, INVE-B.ST, JDG.L:** These models use very grounded assumptions. Growth rates are modeled at a sustainable 10-15%, and base exit P/Es (20-22x) closely mirror their current forward valuations. These represent realistic "steady state" expectations without relying on multiple expansion.

## Mean Reversion (Multiple Expansion)
*   **ICLR (ICON plc) & IT (Gartner):** Modeled with base exit P/Es of 20x, which represents an expansion from their currently quoted forward P/Es (7.7x for ICLR and 11.1x for IT). Given the historical multiples for high-quality CROs and data monopolies, 20x is a realistic reversion to the mean rather than unwarranted optimism. (Note: The deeply compressed forward P/Es currently quoted may also be a result of near-term earnings anomalies).


---

# Financial Assumptions Analysis: Batch 6

## KAP.IL (Kazatomprom)
- **EPS Growth (15%)**: Slightly optimistic for a cyclical commodity producer, but justifiable given structural uranium deficits.
- **Exit P/E (10-15x)**: Realistic and conservative, appropriate for the mining sector.
- **Verdict**: Realistic overall, with grounded multiples.

## KKR (KKR & Co.)
- **EPS Growth (20%)**: Aggressive, though supported by strong management guidance and alt-asset tailwinds.
- **Exit P/E (15-25x)**: Base of 20x is slightly optimistic for a financial, but defensible given their high ROE and permanent capital base.
- **Verdict**: Optimistic but justifiable based on quality.

## KNSL (Kinsale Capital)
- **EPS Growth (15%)**: Realistic, trailing their historical 20-30% compounding rate.
- **Exit P/E (15-25x)**: Base of 20x is well-grounded for a high-growth E&S insurer with a 29% ROE.
- **Verdict**: Realistic and appropriately conservative.

## KYCCF (Keyence Corporation)
- **EPS Growth (8%)**: Realistic for a mature hardware manufacturer.
- **Exit P/E (28-38x)**: Base of 33x is highly optimistic for 8% growth. While they command a historical premium due to margins, it leaves them vulnerable to multiple contraction.
- **Verdict**: Aggressive/optimistic on multiples.

## LAGR-B.ST (Lagercrantz Group)
- **EPS Growth (15%)**: Realistic, consistent with their established M&A compounding model.
- **Exit P/E (15-25x)**: Base of 20x correctly models significant multiple compression from their current ~38x P/E, which is prudent.
- **Verdict**: Realistic and conservative.

## LIFCO-B.ST (Lifco AB)
- **EPS Growth (12%)**: Plausible via M&A.
- **Exit P/E (28-42x)**: Base of 35x is extremely optimistic and borderline unrealistic for cyclical physical industrials. It provides zero margin of safety against macroeconomic slowdowns.
- **Verdict**: Unrealistic/highly optimistic exit multiples.

## LLY (Eli Lilly)
- **EPS Growth (24%)**: Aggressive but anchored in the reality of the GLP-1 hypergrowth cycle.
- **Exit P/E (25-35x)**: Base of 30x realistically models multiple contraction as the company matures post-hypergrowth.
- **Verdict**: Realistic, balancing high growth with multiple compression.

## LMN.V (Lumine Group)
- **EPS Growth (17%)**: Plausible for a serial acquirer with a proven turnaround model.
- **Exit P/E (18-26x)**: Base of 22x is fair to slightly optimistic considering the telecom software end-market lacks strong organic growth.
- **Verdict**: Realistic to slightly optimistic.

## LNG (Cheniere Energy)
- **EPS Growth (4%)**: Conservative and realistic, accounting for mean-reversion.
- **Exit P/E (10-16x)**: Base of 13x is highly appropriate and grounded for capital-intensive energy infrastructure.
- **Verdict**: Realistic and conservative.

## MA (Mastercard)
- **EPS Growth (15%)**: Slightly optimistic given their massive scale and mature global penetration.
- **Exit P/E (30-46x)**: Base of 38x is very aggressive. While matching historical averages, it leaves no room for multiple compression if growth decelerates.
- **Verdict**: Optimistic on both growth and multiples.

---

# Stock Assumptions Analysis - Batch 7

*   **MCK (McKesson):** 15% EPS growth may be slightly optimistic for a mature oligopoly, but massive buybacks support this. The exit P/E range (15-25) is realistic and appropriate for a drug distributor.
*   **MCO (Moody's):** 15% EPS growth is highly realistic given their duopoly pricing power. However, the exit P/E range (15-25, base 20) is likely too pessimistic. Moody's historically commands a premium multiple (25-35x) due to its moat and asset-light model.
*   **MEDP (Medpace):** 15% EPS growth is fairly conservative given historical compounding at 20%+. The exit P/E range (15-25) is reasonable and safe.
*   **MELI (MercadoLibre):** 25% EPS growth is aggressive but realistic for an emerging market e-commerce/fintech dominant player. The exit P/E (base 35) accurately reflects the high-growth premium.
*   **META (Meta Platforms):** 19% EPS growth over 5 years might be slightly optimistic due to the law of large numbers. A base exit P/E of 26 could also be somewhat optimistic for a mature ad-tech company, as multiples tend to compress towards 15-20x as growth slows.
*   **MKL (Markel Group):** 8% EPS growth and exit P/E of 12-20 are well-grounded and realistic for a specialty insurer/compounder undergoing restructuring.
*   **MKTX (MarketAxess):** 15% EPS growth and 15-25 exit P/E are realistic and well-aligned with current valuations and secular tailwinds in electronic bond trading.
*   **MRVL (Marvell Technology):** 30% EPS growth over 5 years is highly aggressive and assumes perfect execution in AI without cyclical drag from enterprise networking. The base exit P/E of 32 is also quite optimistic for a semiconductor stock.
*   **MTRN (Materion):** 15% EPS growth and an exit P/E of 22 (base) are arguably too optimistic for an industrial materials company subject to cyclicality. Materials companies typically trade at lower multiples (12-18x).
*   **MU (Micron Technology):** As noted, the stock is disqualified due to cyclicality. However, assuming an exit P/E of 20 for a highly cyclical memory stock is generally too optimistic unless explicitly applied to trough or normalized earnings, as peak-cycle P/Es usually compress to single digits.

---

# Assumptions Analysis: Batch 8

*   **NBIX (Neurocrine Biosciences):** Realistic. 18% EPS growth aligns with management guidance. Exit P/E (20-28x) is reasonable for a specialty pharma company, though slightly optimistic at the higher end if the pipeline fails to deliver beyond the core drug.
*   **NET (Cloudflare):** Highly Optimistic Multiple. 27% growth is plausible, but an exit P/E of 80-110x in year 5 is exceptionally rich for a maturing software company, leaving zero room for typical multiple compression.
*   **NNI (Nelnet):** Realistic/Conservative. 9% growth and 10-18x exit P/E fit its value-oriented, capital-compounding profile perfectly.
*   **NOW (ServiceNow):** Realistic. 21% growth and 30-45x exit P/E are standard and justifiable for a high-margin, sticky enterprise SaaS monopoly with strong FCF.
*   **NU (Nu Holdings):** Realistic. 28% growth is aggressive but supported by its hyper-growth trajectory and elite >30% ROE. Exit P/E of 20-30x is fair for a dominant fintech platform.
*   **NVDA (NVIDIA):** Highly Optimistic. Assuming 35% annualized EPS growth over 5 years for a ~$4.5T company challenges the law of large numbers. An exit P/E of 55x is also extremely high for cyclical hardware/semiconductors at maturity (historically 15-25x).
*   **OWL (Blue Owl Capital):** Methodologically Flawed (Flagged correctly). Valuing based on GAAP EPS is distorted by acquisition amortization; Fee-Related Earnings (FRE) must be used. Otherwise, 15% growth and 8-13x exit P/E are reasonable for alternative asset managers.
*   **PANW (Palo Alto Networks):** Realistic. 20% growth and 25-42x exit P/E accurately reflect its transition into a maturing cybersecurity platform leader.
*   **PDD (PDD Holdings):** Conservative/Realistic. 18% growth is achievable, and the low exit P/E (8-18x) properly prices in the severe geopolitical, tariff, and regulatory risks.
*   **PLTR (Palantir):** Optimistic. 35% sustained EPS growth over 5 years is very aggressive for enterprise/government software. Even with a highly optimistic exit P/E of 45-60x, the model projects negative returns, underscoring an extreme starting valuation disconnect.

---

# Assumption Analysis: Batch 9

*   **PSK.TO (PrairieSky Royalty):** 15% EPS growth is slightly aggressive for a mature, no-capex royalty company unless banking on sustained energy price inflation. Exit P/Es (15-25x) are realistic and conservative relative to the current 34x forward P/E.
*   **RBRK (Rubrik):** Pre-profit SaaS company. Suspending the P/E-based CAGR model (0% growth, 0x exit P/E) is the correct and realistic approach.
*   **REGN (Regeneron Pharmaceuticals):** 12% EPS growth aligns well with its strong R&D pipeline. Exit P/Es (14-22x) are realistic and conservatively straddle the current 14.3x forward P/E.
*   **RGLD (Royal Gold):** 12% EPS growth is reasonable post-acquisition. However, exit P/Es (18-30x) are optimistic relative to the 16.9x forward P/E, especially given the execution concerns noted in the bear case.
*   **ROP (Roper Technologies):** **Overly Optimistic Multiple.** While 12% EPS growth is solid, modeling an exit P/E of 35x (base) when the current forward P/E is only 15.1x bakes in massive multiple expansion, drastically inflating the expected CAGR (17%).
*   **RXRX (Recursion Pharmaceuticals):** Properly disqualified. Pre-revenue biotech with venture-style binary outcomes cannot be modeled using a standard EPS compounding formula.
*   **SE (Sea Limited):** 30% EPS growth is aggressive but plausible during a margin expansion phase. Exit P/Es (20-30x) are slightly optimistic compared to the 17.3x forward P/E, assuming multiple expansion.
*   **SHOP (Shopify):** 26% EPS growth is realistic for its market position. Exit P/Es (35-55x) are appropriately modeled to normalize sideways or downwards from the current 54.8x forward P/E.
*   **SMSN.IL (Samsung Electronics):** **Critical Data Error.** The model assumes a 47% dividend yield, which completely breaks the CAGR model and artificially inflates the base case return to 38%. This needs immediate correction.
*   **SNPS (Synopsys):** Contradictory data. The narrative cites a 75.8x forward P/E, while the data object lists 25x. If 25x is accurate, exit P/Es of 28-42x are optimistic and rely on multiple expansion. If 75.8x is accurate, the exit multiples model an appropriate contraction.


---

# Analysis of Assumptions - Batch 10

Based on financial principles and industry contexts, here is an analysis of the assumptions (CAGR and Exit Multiples) for the 10 requested stocks:

*   **SPGI (S&P Global):** EPS growth of 15% is realistic given its immense pricing power. However, the exit P/E (Base 20x) is **pessimistic**. High-quality, asset-light data monopolies typically sustain mid-to-high 20s multiples.
*   **TDG (TransDigm Group):** 18% EPS growth is ambitious but historically precedented via M&A. The exit P/E (Base 46x) is **highly optimistic**. Relying on a 46x terminal multiple for a cyclical industrial company with 5.7x leverage is risky and leaves little margin of safety.
*   **TFPM (Triple Flag Precious Metals):** Assumptions are **realistic**. 8% growth and a 23x base exit P/E align well with precious metal streaming models, which correctly command premium multiples compared to traditional miners.
*   **TOI.V (Topicus.com):** 25% EPS growth is aggressive but achievable given their track record. The exit P/E (Base 54x) is **highly optimistic**. Assuming a 54x terminal multiple prices in absolute perfection and ignores potential macroeconomic slowdowns in Europe.
*   **TPL (Texas Pacific Land):** Both 15% growth and a 35x base exit P/E are **optimistic**. While margins are world-class, it is still exposed to cyclical oil drilling. A 35x multiple heavily prices in speculative data center success rather than its core royalty business.
*   **TPZ.TO (Topaz Energy):** 15% EPS growth is **optimistic** for a natural gas royalty company, as structural 15% growth usually requires continuous commodity price tailwinds or massive volume expansions.
*   **TSM (TSMC):** 28% EPS growth over a 5-year horizon is **very optimistic**. Sustaining a 28% CAGR on a ~$1.8T base assumes the AI boom perfectly offsets all standard semiconductor cyclicality. Exit P/Es (Base 28x) represent a structural re-rating from historical norms.
*   **TVK.TO (TerraVest Industries):** Assumptions are **realistic and prudent**. 15% EPS growth is achievable for a disciplined serial acquirer, and assuming multiple compression down to a 20x base exit P/E (from the current ~32x) is appropriately conservative.
*   **TW (Tradeweb):** 15% EPS growth is realistic, but the exit P/E (Base 20x) is **pessimistic**. Electronic trading duopolies with massive operating leverage and asset-light models usually sustain multiples well above 20x.
*   **UBER (Uber Technologies):** 15% EPS growth is **pessimistic**, especially since the file notes forward EPS growth projections of 20-40% due to operating leverage. The 20x base exit P/E is also somewhat conservative for a dominant consumer tech monopoly hitting its free cash flow inflection point.

---

# Assumptions Analysis - Batch 11

## Findings

*   **URI (United Rentals):** EPS growth of 15% may be slightly optimistic for a cyclical industrial, despite infrastructure tailwinds. A base exit P/E of 20 is higher than its historical average, which is typically in the low-to-mid teens.
*   **V (Visa):** 14% EPS growth is plausible but potentially optimistic given its mature, massive scale. A base exit P/E of 35 is steep, even for a high-quality compounder.
*   **VEEV (Veeva Systems):** 19% EPS growth is aggressive if top-line growth is decelerating to 16%, relying heavily on margin expansion. The base exit P/E of 45 is very rich and leaves little room for execution error.
*   **VIT-B.ST (Vitec Software):** 12% EPS growth and a 25x base exit P/E appear realistic and well-calibrated for a quality serial acquirer model.
*   **VNOM (Viper Energy):** 8% EPS growth assumes favorable oil prices and/or acquisitions. A base exit P/E of 11 is reasonable for an energy royalty.
*   **VRSK (Verisk Analytics):** 15% EPS growth is solid. A base exit P/E of 20 is arguably too conservative for a high-margin data monopoly, which often trades at >25x.
*   **VRT (Vertiv):** 30% EPS growth is extremely aggressive, albeit aligned with current AI tailwinds. The base exit P/E of 35 is risky for an industrial hardware company if the AI capex cycle cools. Highly optimistic.
*   **VRTX (Vertex Pharmaceuticals):** 13% EPS growth seems slightly optimistic if top-line revenue is guiding for 8.5-9% growth, implying heavy reliance on margin expansion/buybacks. The 25x base P/E is fair.
*   **WPM (Wheaton Precious Metals):** 15% EPS growth assumes sustained high precious metals prices and flawless production execution. 27x base exit P/E is typical for the space.
*   **WSO (Watsco):** 15% EPS growth is slightly aggressive long-term for HVAC distribution but possible given its M&A strategy. 20x base P/E is fair.
*   **WST (West Pharmaceutical):** 15% EPS growth is realistic. A 20x base exit P/E is likely conservative, given its near-monopoly status and historically higher multiples.
*   **XYZ (Block Inc.):** 12% EPS growth is realistic amidst cost-cutting. A 30x base exit P/E is somewhat optimistic for a company with "razor-thin" margins and intense competition.
*   **ZS (Zscaler):** 24% EPS growth is realistic given 25-35% revenue growth. A 32x base exit P/E represents a significant premium, requiring sustained high growth.
*   **ZTS (Zoetis):** 15% EPS growth is achievable. A 20x base exit P/E is conservative; Zoetis typically commands a premium multiple (>25x) due to its durable animal health monopoly.